Pamrevlumab

Pamrevlumab (also known as FG-3019) is an experimental drug developed by FibroGen for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. It is a human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic diseases and cancer.

Mechanism of Action

Pamrevlumab works by binding to and inhibiting the activity of CTGF, a protein that is overexpressed in many fibrotic diseases and cancers. By blocking the activity of CTGF, pamrevlumab can potentially slow down or halt the progression of these diseases.

Clinical Trials

Pamrevlumab has undergone several clinical trials for different indications. In a Phase 2 trial for idiopathic pulmonary fibrosis, the drug showed a significant reduction in disease progression compared to placebo. It is currently in Phase 3 trials for this indication.

For pancreatic cancer, pamrevlumab has shown promise in combination with gemcitabine and nab-paclitaxel in a Phase 2 trial. The drug is also in Phase 2 trials for Duchenne muscular dystrophy.

Potential Side Effects

As with any drug, pamrevlumab may cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. However, the severity and frequency of these side effects can vary among individuals.

See Also

• FibroGen
• Idiopathic pulmonary fibrosis
• Pancreatic cancer
• Duchenne muscular dystrophy
• Connective tissue growth factor
• Clinical trial